The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival from the open label phase 2 trial of palbociclib in patients with advanced well differentiated/dedifferentiated liposarcoma.
 
Olayode Babatunde
Stock and Other Ownership Interests - Novo Nordisk
 
Gary Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq
Consulting or Advisory Role - Bionaut Labs; Concarlo; Ipsen; OnCusp Therapeutics; PTC Therapeutics; Ratiopharm
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
 
Mary Louise Keohan
No Relationships to Disclose
 
Sandra D'Angelo
Honoraria - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Medendi; Nektar; Pfizer; Rain Therapeutics; Ratio therapeutics; Replimune; Servier
Research Funding - Amgen; Bristol-Myers Squibb.; Deciphera; EMD Serono; Incyte; Merck; Nektar
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
Other Relationship - Adaptimmune; GlaxoSmithKline; Merck; Nektar
 
Mrinal Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Epizyme; Ikena Oncology; Kura Oncology; Rain Therapeutics
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Vivace Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
Travel, Accommodations, Expenses - NewBay Pharma
 
Cristina Antonescu
No Relationships to Disclose
 
Jonathan Landa
No Relationships to Disclose
 
Kenneth Seier
No Relationships to Disclose
 
Li-Xuan Qin
Employment - Sironax (I)
Leadership - Sironax (I)
Stock and Other Ownership Interests - Sironax (I)
 
Aimee Crago
Honoraria - Wolters Kluwer
Consulting or Advisory Role - Springworks Therapeutics
Patents, Royalties, Other Intellectual Property - Patent assigned to MSKCC for a companion diagnostic to CDK4 inhibitors - Patent number 9,889,135 (Inst)
Travel, Accommodations, Expenses - Deciphera
 
Samuel Singer
No Relationships to Disclose
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Avacta Life Sciences; Bayer; Boehringer Ingelheim; C4 Therapeutics; Curadev; Daiichi Sankyo; Deciphera; Ikena Oncology; IMGT; inhibrx; Ipsen; PharmaEssential; Ratio; Servier; Sonata
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Mark Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)